Matching trials
1,853 results
- SGA-POWERIndependent statistical analysis of Neuromuscular Changes In Small For Gestational Age Children During Somatropin Therapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- SHARPIndependent statistical analysis of SHARP, the randomized phase 3 study of sorafenib versus placebo in patients with advanced hepatocellular carcinoma, including its overall survival and symptomatic progression endpoints, stratified log-rank methodology, interim…
- SHIELDIndependent statistical analysis of 38 Week Extension Study to CAIN457C2303: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01093846).
- SHIELDIndependent statistical analysis of Phase III Study in Refractory Behcet's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00995709).
- SHINEIndependent statistical analysis of A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- SHOCKIndependent statistical analysis of the SHOCK phase 3 trial of extracorporal cytokine removal in septic shock, covering its randomized three-arm design, shock reversal endpoints, planned time-to-event analysis, and statistical interpretation.
- SICOG 0109Independent statistical analysis of Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SINGLEComplete statistical analysis of the SINGLE phase 3 trial comparing dolutegravir plus abacavir/lamivudine with Atripla in HIV-1 infection, including the Week 48 primary endpoint, later virologic suppression analyses, CD4 outcomes, non-inferiority methodology,…
- SINUS-52Independent statistical analysis of Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02898454).
- SirolimusIndependent statistical analysis of Pharmacokinetics of Sirolimus and Tacrolimus in Liver Transplant Recipients With Tacrolimus Toxicity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SISTErIndependent statistical analysis of Comparison of Surgical Procedures to Reduce Urinary Stress Incontinence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00064662).
- Skylight 2Independent statistical analysis of A Study to Find Out if Fezolinetant Helps Reduce Moderate to Severe Hot Flashes in Women Going Through Menopause - 2: primary endpoint results, effect estimate with confidence…
- SKYSCRAPER-06Independent statistical analysis of SKYSCRAPER-06, evaluating tiragolumab plus atezolizumab and chemotherapy versus pembrolizumab plus chemotherapy in previously untreated advanced non-squamous NSCLC, with detailed interpretation of PFS, OS, response, quality-of-life, and safety analyses.
- SMARTIndependent statistical analysis of SMART (NCT02477397), a randomized phase 3 trial comparing Spiromax budesonide/formoterol with Diskus fluticasone/salmeterol in COPD, including its design, symptom endpoint, planned analysis, and statistical interpretation.
- SNOCATIndependent statistical analysis of SNOCAT, a randomized phase 2/3 trial of sodium nitrite versus placebo for out-of-hospital cardiac arrest, including primary survival results, secondary endpoints, statistical methods, and interpretation.
- SOCRATESIndependent statistical analysis of the SOCRATES phase 3 trial of ticagrelor versus acetylsalicylic acid after acute ischaemic stroke or transient ischaemic attack, including endpoint definitions, Cox and logistic regression methods, efficacy results,…
- SOFTIndependent statistical analysis of the SOFT phase 3 trial of tamoxifen, tamoxifen plus ovarian function suppression, and exemestane plus ovarian function suppression in premenopausal women with hormone-responsive breast cancer.
- SOLO1Complete statistical analysis of SOLO1, a randomized phase 3 trial of olaparib maintenance monotherapy versus placebo in BRCA-mutated advanced ovarian cancer following first-line platinum-based chemotherapy.
- SOLO3Independent statistical analysis of the SOLO3 phase 3 trial of olaparib versus single-agent chemotherapy in relapsed germline BRCA-mutated ovarian cancer, including trial design, objective response, survival endpoints, statistical methods, safety, and interpretation.
- SOLO3Independent statistical analysis of Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received…
- SOLOIST-WHFIndependent statistical analysis of SOLOIST-WHF (NCT03521934), evaluating sotagliflozin versus placebo in participants with type 2 diabetes and worsening heart failure. Includes trial design, registered endpoints, Cox, ANCOVA and MMRM methodology, reported results,…
- SONARIndependent statistical analysis of the phase 3 SONAR trial of atrasentan versus placebo in diabetic nephropathy, including the composite renal endpoint, hazard ratios, confidence intervals, p-values, trial design, and statistical methodology.
- SORAYAIndependent statistical analysis of the phase 3 SORAYA trial of mirvetuximab soravtansine in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
- SPARKIndependent statistical analysis of Kuvan® in Phenylketonuria Patients Less Than 4 Years Old: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01376908).
- SPARTANIndependent statistical analysis of the phase 3 SPARTAN trial of apalutamide versus placebo in men with non-metastatic castration-resistant prostate cancer, including metastasis-free survival, time to metastasis, progression-free survival, statistical methodology, safety, and…
- SPIRE-1An independent statistical analysis of SPIRE-1 (NCT01975376), the terminated phase 3 placebo-controlled trial of bococizumab for prevention of major cardiovascular events: stratified Cox hazard ratios, MMRM and ANCOVA lipid analyses, multiplicity and…
- SPIRE-2Independent statistical analysis of SPIRE-2 (NCT01975389), the terminated phase 3 placebo-controlled trial of bococizumab in high-risk participants: stratified Cox hazard ratios for major cardiovascular events, MMRM and ANCOVA lipid analyses, and serious…
- SPIRE-HRIndependent statistical analysis of Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events: primary endpoint results, effect estimate with confidence interval, sample-size…
- SPIRITIndependent statistical analysis of Randomized Placebo-controlled Study of ISA247 in Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00244842).
- SPRING-2Independent statistical analysis of A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- SPRINT-2Independent statistical analysis of SPRINT-2, a randomized phase 3 trial of boceprevir plus peginterferon alfa-2b and ribavirin in previously untreated adults with chronic hepatitis C genotype 1.
- SPS3A detailed statistical review of SPS3, a randomized phase 3 trial of secondary prevention of small subcortical strokes, including its trial design, registered endpoints, planned statistical analysis, and interpretation.
- STAGEIndependent statistical analysis of A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- STAGED-PKD-EXTIndependent statistical analysis of Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- STAR-TRECIndependent statistical analysis of STAR-TREC (NCT02945566), a randomized phase 2/3 trial evaluating organ preservation strategies versus total mesorectal excision for early rectal cancer.
- STARTComplete statistical analysis of START, a randomized phase 3 trial of tecemotide (L-BLP25) plus cyclophosphamide versus saline plus placebo in unresectable stage III non-small cell lung cancer, including overall survival, symptom progression,…
- STATUREIndependent statistical analysis of Efficacy and Safety of Intravenous and Subcutaneous Secukinumab in Moderate to Severe Chronic Plaque-type Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- STEADFASTIndependent statistical analysis of Long-Term Safety Extension Study of ACTIMMUNE® (Interferon γ-1b) in Children and Young Adults With Friedreich's Ataxia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- STEP 4Independent statistical analysis of STEP 4 (NCT03548987), a randomized phase 3 trial evaluating change in body weight with semaglutide 2.4 mg versus placebo in people with overweight or obesity.
- STEP 5Complete statistical analysis of the STEP 5 phase 3 trial of semaglutide versus placebo in adults with overweight or obesity, including trial design, primary endpoints, ANCOVA, MMRM, logistic regression, confidence intervals, and…
- STEP UPComplete statistical analysis of the STEP UP phase 3 trial of semaglutide 7.2 mg versus placebo in people with obesity, including trial design, primary endpoints, ANCOVA, odds ratios, confidence intervals, p-values, safety,…
- STEP-IPFIndependent statistical analysis of STEP-IPF (NCT00517933), a randomized phase 3 trial of sildenafil versus placebo in patients with pulmonary fibrosis and pulmonary hypertension, including endpoint definitions, reported statistical analyses, interpretation, and limitations.
- STEP12Independent statistical analysis of A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range: primary endpoint results, effect estimate with confidence interval,…
- STOP-NIDDMIndependent statistical analysis of STOP-NIDDM, a randomized phase 3 trial evaluating acarbose versus placebo for incidence of newly diagnosed type 2 diabetes in participants with metabolic syndrome.
- STRENGTHIndependent statistical analysis of Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- STRIDEComplete statistical analysis of the STRIDE phase 3 trial of evidence-based tailored fall prevention versus usual care, including trial design, time-to-event analysis, longitudinal outcomes, safety, and statistical interpretation.
- STRIVEComplete statistical analysis of the STRIVE phase 3 trial of erenumab for migraine prevention, including randomized trial design, primary and secondary endpoint analyses, mixed-effects models, Cochran-Mantel-Haenszel testing, multiplicity, and safety.
- SUCCESS CA statistical analysis of SUCCESS C, a phase 3 randomized breast cancer trial evaluating docetaxel-based adjuvant treatment strategies and disease-free survival methodology.
- SUMMITIndependent statistical analysis of A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- SUMMIT-LTSIndependent statistical analysis of Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer Pain: primary endpoint results, effect estimate with confidence interval, sample-size planning…